|
Metir PLC on Tuesday said it is trading in line with expectations but that investment in manufacturing growth and product development will prevent full-year profitability. The York, England-based company focused on water testing services said demand is increasing, fuelled by growing international demand for Microtox LX instruments, reagents and SRB sales. Sales are in line with management expectations, Metir said in a trading update. Having invested in manufacturing growth and product development, the company said that earnings before interest, taxes, depreciation, and amortisation profitability is ‘likely to be deferred’ until 2026. Nearing the limits of its current outsourced manufacturing capacity, the company said that it is in talks with its manufacturing partner to increase production rates in 2026. It also intends to further upgrade the LX and FX units, which it said will improve instrument margins. Regarding the Qatar project, Metir said it agreed to a deferred payment schedule with its partner Avanceon. It added that it expects new reagent revenue to start during early 2027. As of December 1, the group’s cash balance is £147,000, which it said is ‘slightly lower than forecast’. ‘Looking ahead to 2026, Metir will enter the year with strong momentum in instrument sales, an expanding international footprint of installed instruments, and enhanced sales and customer support capability,’ said Executive Chair and Chief Executive Bob Moore. ‘The group has invested in manufacturing growth and product development which includes use of proceeds of the successful June 2025 fund raise.’ Shares in Metir fell 6.4% to 0.77 pence on Tuesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
